Official Congress Report

The Challenge of Drug-Induced Liver Injury (DILI)

Falk Workshop
Freiburg, October 9, 2014

Editors
A.L. Gerbes, Munich
H.W. Jaeschke, Kansas City, Mo.

Challenges and Management of Liver Cirrhosis

Falk Symposium 195
Freiburg, October 10–11, 2014

Editors
A.L. Gerbes, Munich
J. Bosch, Barcelona
M. Pinzani, London
F. Wong, Toronto, Que.

30 figures and 22 tables, 2015
Contents

457 Preface
Gerbes, A.L., (Munich); Jaeschke, H. (Kansas City, Kans.)

Understanding the Problem of DILI

458 Drug-Induced Liver Injury Is a Major Risk for New Drugs
Seeff, L.B. (Philadelphia, Pa.)

464 Acetaminophen: Dose-Dependent Drug Hepatotoxicity and Acute Liver Failure in Patients
Jaeschke, H. (Kansas City, Kans.)

472 How to Diagnose and Exclude Drug-Induced Liver Injury
Watkins, P.B. (Chapel Hill, N.C.)

477 Preventing Drug-Induced Liver Injury: How Useful Are Animal Models?
Ballet, F. (Paris)

Dealing with DILI in Drug Development

486 Drug-Induced Liver Injury and Individual Cell Models
Benesic, A. (Munich/Martinsried); Gerbes, A.L. (Munich)

Fibrosis: Pathophysiology, Diagnosis and Treatment

492 Pathophysiology of Liver Fibrosis
Pinzani, M. (London)

498 Noninvasive Assessment of Liver Fibrosis
Castera, L. (Clichy)

504 Hepatic Fibrosis: Emerging Therapies
Friedman, S.L. (New York, N.Y.)

Portal Hypertension and Complications

508 Pathophysiology and a Rational Basis of Therapy
Gracia-Sancho, J.; Maeso-Díaz, R.; Bosch, J. (Barcelona)

515 Clinical Evaluation and Prognosis
Hernández-Gea, V.; Berzigotti, A. (Barcelona)

524 Therapies: Drugs, Scopes and Transjugular Intrahepatic Portosystemic Shunt – When and How?
Abraldes, J.G.; Tandon, P. (Edmonton, Alta.)